Relieves discomfort associated with acute, painful musculoskeletal conditions. ANDA 207237, held by Mpp Pharma. Carisoprodol.
As of Nov 16, 2026, ANDA 207237 (Carisoprodol), held by Mpp Pharma, was first approved by FDA on May 11, 2017, with 1 approved supplement and 0 published complete response letters.
Carisoprodol tablets are indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults. Limitation of Use Carisoprodol tablets should only be used for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use has not been established and because acute, painful musculoskeletal conditions are generally of short duration.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 11, 2017 | Original application | Approved | None posted |
| Carisoprodol250MG · tablet;oral | Carisoprodol | Rx |
| Carisoprodol350MG · tablet;oral | Carisoprodol | Rx |
| May 1, 2020 | Supplement 2Labeling · Standard review | Approved | None posted |
| May 11, 2017 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters